Investor Presentaiton

Pharmaceuticals Segment Highlights - Q3'FY20 (2/2) Facility USFDA Inspection Details Last Inspection Generics¹ Montreal, CMO May, 2018 Montreal, Radiopharma Sep, 2017 Salisbury May, 2018 • Spokane July, 2019 Roorkee Nov, 2019 Nanjangud Dec, 2018 Product Pipeline as on Dec 31, 2019 Dosage (Orals) (#) . Revenue was flat YoY and down 2% QoQ primarily due to lower volumes in some key products due to customer scheduling Better pricing in certain products due to favourable market conditions Received ANDA approval for Clomipramine HCL Capsule from Salisbury facility during the quarter Roorkee WL Remediation process progressing well in consultation with 3rd party consultants to address US FDA observations. ■ Pharmaceuticals EBITDA at Rs 411 Crore increased by 6% YoY and 7% QoQ with a margin of 28.4% as compared to 27.2% in Q3'FY19 and 26.6% in Q2'FY20. Better margins in Specialty pharmaceuticals and Generics businesses during the quarter ■ Pharmaceuticals adjusted EBITDA at Rs 414 Crore increased by 8% YoY with a margin of 28.6% as compared to 26.9% in Q3'FY19 Filings Approved Pending . US 98 62 36 Canada 23 23 0 Europe 37 33 4 ROW 41 36 5 Steriles (#) Filings Approved Pending US 15 13 2 Canada 17 16 1 Europe 4 4 0 ROW 9 9 0 One-off expenses of Rs 3 Crore related to site remediation and litigation expenses R&D spent during the quarter of Rs. 72 Crore - 5% to segment sales. R&D debited to P&L is Rs. 55 Crore - 3.8% to segment sales 1. Generics business refers to the company's solid dosage formulations business and the India Branded Pharmaceuticals business JUBILANT LIFESCIENCES

View entire presentation